Aller au contenu principal
2019 conference-abstract

ESRA19-0085 Reduction of pain medications with subcutaneous peripheral nerve stimulation: data from the subqstim rct

0Citations signalées — pas une note de qualité
4Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

Background and aims The SubQStim study showed subcutaneous nerve stimulation (SQS) plus optimized medical management (OMM) was more effective in reducing back pain than OMM alone in patients with failed back surgery syndrome.1 We explore the use of pain medications by the study participants. Methods Ethics committee approval was obtained for each site. Analysis of prescribed pain medications between the SQS+OMM (n=38) and OMM (n=36) arms from baseline through 9-months post-randomization was performed using descriptive statistics and complete cases approach. Total daily dose was calculated by multiplying the prescribed dose by quantity and then by daily frequency. Morphine Milligram Equivalent (MME) dose was calculated by multiplying the total daily dose of each applicable opioid by the MME conversion factor.2 Results From baseline to 9 months, the SQS+OMM arm showed a decrease in the proportion of subjects on NSAIDs (-7.9%) and opioids (-10.5%), whereas the OMM arm showed a slight reduction in antidepressants (-2.8%) and other category (-2.8%) (figure 1). Most subjects (64%) were taking opioids at baseline. From baseline to 9 months, mean MME dose increased by 8.8 mg in the OMM arm (42.5±92.1 to 51.2±107.2); whereas the SQS+OMM arm decreased by 8.9 mg (29.8±42.3 to 20.9±37.3)(figure 2–3). At 9 months, 31.6% of SQS+OMM subjects reduced MME compared to 8.3% of OMM subjects. Only 13.2% of SQS+OMM subjects had an increase in MME opioids compared to 27.8% of OMM subjects. Conclusions There is a positive trend that pain medication and morphine intake as assessed by MME may be reduced in patients receiving SQS. References Eldabe SS, et al. Neuromodulation 2018; DOI:10.1111/ner.12784. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-vFeb-2018.pdf

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
ESRA19-0085 Reduction of pain medications with subcutaneous peripheral nerve stimulation: data from the subqstim rct
Date Crossref
30/08/2019
Éditeur
BMJ Publishing Group Ltd
Type
proceedings-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Pain Management and TreatmentMusculoskeletal pain and rehabilitationBotulinum Toxin and Related Neurological Disorders

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.